AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30357066 — intervention group
Group type: EXPERIMENTAL
Intervention: hEAR mobile application with Sennheiser HD280 Pro headphones
Number of subjects: 30
Study 30357066 — intervention group
Group type: COMPARATOR
Intervention: Pure tone audiometric tests administered by an audiologist
Number of subjects: 30
Study 26926659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Number of subjects: 176
Study 26926659 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST)
Number of subjects: 176
Study 26926659 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 176
Study 26926659 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle psychoeducation
Number of subjects: 176
Study 25262862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping and ablation of autonomic ganglia (AGP+)
Number of subjects: 47
Study 25262862 — intervention group
Group type: COMPARATOR
Intervention: No mapping and ablation (AGP-)
Number of subjects: 47
Study 22665430 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual quizzes (intervention group I, n = 57)
Number of subjects: 155
Study 22665430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group quizzes (intervention group II, n = 56)
Number of subjects: 155
Study 22665430 — intervention group
Group type: COMPARATOR
Intervention: No quizzes (control; intervention group III, n = 42)
Number of subjects: 155
Study 18663642 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional visual scanning training combined with electrostimulation of the left hand
Number of subjects: 40
Study 18663642 — intervention group
Group type: COMPARATOR
Intervention: Scanning training with sham stimulation
Number of subjects: 40
Study 17767479 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (four 90-min sessions in small groups)
Number of subjects: 98
Study 17767479 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 98
Study 17767479 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (CON)
Number of subjects: 98
Study 14962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic anemia (IA)
Number of subjects: 60
Study 14962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia
Number of subjects: 60
Study 14962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia associated with chronic disease
Number of subjects: 60
Study 14962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia of renal insufficiency
Number of subjects: 60
Study 14962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Other causes of anemia
Number of subjects: 60
Study 11472284 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injection without iv carrier fluid
Number of subjects: 30
Study 11472284 — intervention group
Group type: COMPARATOR
Intervention: Propofol injection with iv carrier fluid
Number of subjects: 30
Study 9531581 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli‐derived GM‐CSF (5 micrograms/kg/d by 6‐hour intravenous infusion) during induction chemotherapy.
Number of subjects: 240
Study 9531581 — intervention group
Group type: COMPARATOR
Intervention: Placebo during induction chemotherapy.
Number of subjects: 240
Study 8070287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungoid Tincture
Number of subjects: 20
Study 8070287 — intervention group
Group type: COMPARATOR
Intervention: Vehicle Control
Number of subjects: 20
Study 3281127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-protoporphyrin
Number of subjects: 122
Study 3281127 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study 1363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg o.d.)
Number of subjects: 7
Study 1363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (400 mg o.d.)
Number of subjects: 7
Study 1363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg o.d.)
Number of subjects: 7
Study 1363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg o.d.)
Number of subjects: 7
Study 1363660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 319711 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 21
Study 319711 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 21
Study 319711 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 21
Study 31056824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hard palate closure (EHPC) at 12 months
Number of subjects: 122
Study 31056824 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed hard palate closure (DHPC) at 36 months
Number of subjects: 122
Study 31056824 — intervention group
Group type: COMPARATOR
Intervention: UCLP subjects compared to controls
Number of subjects: 122
Study 31056824 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLP subjects
Number of subjects: 122
Study 28823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care alone
Number of subjects: 1505
Study 28823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily medication reminders via SMS text messages
Number of subjects: 1505
Study 28823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication monitoring via a patient portal-based assessment
Number of subjects: 1505
Study 28823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SMS text message reminders and portal-based medication monitoring
Number of subjects: 1505
Study 28823927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1505
Study 28823927 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention strategies
Number of subjects: 1505
Study 25624429 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel 400 mg plus prednisone 5 mg twice daily
Number of subjects: 1099
Study 25624429 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone 5 mg twice daily
Number of subjects: 1099
Study 24300224 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the primary motor cortex (M1) at 2 mA for 20 minutes on 5 consecutive days.
Number of subjects: 20
Study 24300224 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS.
Number of subjects: 20
Study 24300224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tDCS and sham)
Number of subjects: 20
Study 22033040 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 320/9 μg
Number of subjects: 1219
Study 22033040 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 160/9 μg
Number of subjects: 1219
Study 22033040 — intervention group
Group type: COMPARATOR
Intervention: formoterol dry powder inhaler 9 μg
Number of subjects: 1219
Study 19309745 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents
Number of subjects: 1000
Study 19309745 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 1000
Study 17524018 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive intervention involving an 18-hour course for health visitors, including 1-3 home visits during the first 5 weeks post-partum.
Number of subjects: 1597
Study 17524018 — intervention group
Group type: COMPARATOR
Intervention: Usual practice by health visitors in the comparison group.
Number of subjects: 1597
Study 15212192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-release orodispersible tramadol tablet (Zamadol Melt)
Number of subjects: 20
Study 15212192 — intervention group
Group type: COMPARATOR
Intervention: Conventional tramadol capsule
Number of subjects: 20
Study 11434728 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 528
Study 11434728 — intervention group
Group type: COMPARATOR
Intervention: Not taking HAART
Number of subjects: 528
Study 9700035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with olive-allergen extracts (Stallergènes SA), 20 drops of 300 IR daily for 2 years
Number of subjects: 66
Study 9700035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with olive-allergen extracts (Stallergènes SA)
Number of subjects: 66
Study 9700035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7787006 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects ordinal regression model
Number of subjects: 0
Study 2691496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy for high-risk breast cancer
Number of subjects: 0
Study 2691496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy
Number of subjects: 0
Study 2691496 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary (neoadjuvant) chemotherapy
Number of subjects: 0
Study 2691496 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study 30137340 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg of micafungin twice weekly
Number of subjects: 20
Study 30137340 — intervention group
Group type: COMPARATOR
Intervention: 100mg of micafungin once daily
Number of subjects: 20
Study 30137340 — intervention group
Group type: EXPERIMENTAL
Intervention: 700mg once weekly (hypothetical regimen)
Number of subjects: 20
Study 26873948 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! intervention
Number of subjects: 2532
Study 24533393 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 100
Study 24533393 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 100
Study 22968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery
Number of subjects: 44
Study 22968501 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomic surgery (Control)
Number of subjects: 44
Study 22968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion needed
Number of subjects: 44
Study 20094786 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water instillation
Number of subjects: 117
Study 20094786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil lubrication
Number of subjects: 117
Study 20094786 — intervention group
Group type: COMPARATOR
Intervention: Conventional method with administration of antispasmodics
Number of subjects: 117
Study 18571850 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain threshold measurement at three equidistant sites of both volar forearms
Number of subjects: 18
Study 18571850 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain tolerance measurement at three equidistant sites of both volar forearms
Number of subjects: 18
Study 16020915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 30
Study 16020915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 30
Study 16020915 — intervention group
Group type: COMPARATOR
Intervention: Control (normocholesterolemic type 2 DM patients)
Number of subjects: 30
Study 12525338 — intervention group
Group type: EXPERIMENTAL
Intervention: FACES III questionnaire in Spanish (México)
Number of subjects: 270
Study 10376613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 1804
Study 10376613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study 8785635 — intervention group
Group type: EXPERIMENTAL
Intervention: Two view technique
Number of subjects: 33734
Study 1502960 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) with Haloperidol (30 mg/day)
Number of subjects: 20
Study 1502960 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (30 mg/day)
Number of subjects: 20
Study 6144974 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (CMFp + T)
Number of subjects: 783
Study 6144974 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (p + T)
Number of subjects: 783
Study 6144974 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant treatment)
Number of subjects: 783
Study 29667448 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength colours (blue/purple) with positively framed sunscreen pamphlet
Number of subjects: 286
Study 29667448 — intervention group
Group type: COMPARATOR
Intervention: Long wavelength colours (red/orange) with negatively framed messages
Number of subjects: 286
Study 26661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (0.5 mg)
Number of subjects: 31
Study 26661570 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 31
Study 26661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline motility
Number of subjects: 31
Study 25262519 — intervention group
Group type: EXPERIMENTAL
Intervention: Flying Needle and Chinese herbal medicine
Number of subjects: 30
Study 22209501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with bread (BREAD group)
Number of subjects: 122
Study 22209501 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet without bread (NO BREAD group)
Number of subjects: 122
Study 20233180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg as 30-min intravenous infusion without probenecid
Number of subjects: 12
Study 20233180 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 200 mg as 30-min intravenous infusion with 3 g probenecid divided into five oral doses
Number of subjects: 12
Study 19094670 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day steroid withdrawal group
Number of subjects: 76
Study 19094670 — intervention group
Group type: COMPARATOR
Intervention: 3 month steroid withdrawal group
Number of subjects: 76
Study 19094670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 16197815 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose IGF-1 (3 microg/kg of body weight)
Number of subjects: 9
Study 16197815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose IGF-1 (0.5 microg/kg of body weight)
Number of subjects: 9
Study 16197815 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 12390211 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (lansoprazole, amoxicillin, metronidazole)
Number of subjects: 104
Study 12390211 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus vitamin C (250 mg) and vitamin E (200 mg)
Number of subjects: 104
Study 12390211 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (lansoprazole, amoxicillin, metronidazole) for metronidazole susceptible isolates
Number of subjects: 104
Study 12390211 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus vitamin C and E for metronidazole susceptible isolates
Number of subjects: 104
Study 10558313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation with the Trachlight
Number of subjects: 24
Study 10558313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intubation with the Trachlight
Number of subjects: 24
Study 10558313 — intervention group
Group type: COMPARATOR
Intervention: Nasal and oral intubation
Number of subjects: 24
Study 7747709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 174
Study 7747709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) + Protein-bound polysaccharide (PSK)
Number of subjects: 174
Study 7747709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) + Chemotherapy (CT)
Number of subjects: 174
Study 7747709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) + Chemotherapy (CT) + Protein-bound polysaccharide (PSK)
Number of subjects: 174
Study 2117622 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose pro‐urokinase (9 million U)
Number of subjects: 75
Study 2117622 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (4.5 million U pro‐urokinase and 0.2 million U urokinase)
Number of subjects: 75
Study 2117622 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose pro‐urokinase
Number of subjects: 75
Study 6117684 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (from 200 to 50 mmol/day over 2 weeks)
Number of subjects: 20
Study 6117684 — intervention group
Group type: EXPERIMENTAL
Intervention: High potassium intake
Number of subjects: 20
Study 6117684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low sodium/high potassium intake
Number of subjects: 20
Study 30654145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided rectus sheath block (LGRSB) with ropivacaine hydrochloride
Number of subjects: 210
Study 30654145 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 210
Study 28501884 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (32‐8 mg once daily for 20 days)
Number of subjects: 63
Study 28501884 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (injected every 2 or 4 weeks)
Number of subjects: 63
Study 28501884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (injected at baseline and at 4 weeks)
Number of subjects: 63
Study 28501884 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 20 days)
Number of subjects: 63
Study 25708347 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 30 min)
Number of subjects: 40
Study 25708347 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 23645692 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels ≥ 221 ng/mL (upper quartile)
Number of subjects: 17359
Study 23645692 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels between 221 ng/mL and upper tertile
Number of subjects: 17359
Study 23645692 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels between lower tertile and 221 ng/mL
Number of subjects: 17359
Study 23645692 — intervention group
Group type: COMPARATOR
Intervention: D-dimer levels < 221 ng/mL (reference group)
Number of subjects: 17359
Study 21248401 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM+BT (PTM plus balneotherapy)
Number of subjects: 56
Study 21248401 — intervention group
Group type: COMPARATOR
Intervention: PTM (PTM alone)
Number of subjects: 56
Study 21248401 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM+HT (PTM plus hydrotherapy)
Number of subjects: 56
Study 19409309 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket (group II, n = 22)
Number of subjects: 44
Study 19409309 — intervention group
Group type: COMPARATOR
Intervention: Cotton blanket (group I, n = 22)
Number of subjects: 44
Study 17545090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation at 1 min after rocuronium administration
Number of subjects: 120
Study 17545090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation at 2-4 min after rocuronium administration
Number of subjects: 120
Study 17545090 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of neuromuscular function at 1 min after rocuronium administration
Number of subjects: 120
Study 15336770 — intervention group
Group type: EXPERIMENTAL
Intervention: Atridox (doxycycline)
Number of subjects: 28
Study 15336770 — intervention group
Group type: COMPARATOR
Intervention: Control (no Atridox)
Number of subjects: 28
Study 11118390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (primary and secondary) for Pneumocystis carinii pneumonia
Number of subjects: 531
Study 11118390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for Mycobacterium avium complex
Number of subjects: 531
Study 11118390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for cytomegalovirus
Number of subjects: 531
Study 11118390 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for wasting
Number of subjects: 531
Study 9688002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplements (320 mg twice daily)
Number of subjects: 56
Study 9688002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10207294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg/day and heparansulphate 200 mg/day
Number of subjects: 19
Study 10207294 — intervention group
Group type: COMPARATOR
Intervention: Indobufen 200 mg/day
Number of subjects: 19
Study 1929130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression
Number of subjects: 197
Study 1929130 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric decompression
Number of subjects: 197
Study 6356903 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol alone or in combination with furosemide
Number of subjects: 81
Study 6356903 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa plus furosemide
Number of subjects: 81
Study 31313297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Resilience Program (ARP)
Number of subjects: 76
Study 31313297 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study 31532789 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-IIV3 (trivalent hemagglutinin DNA prime followed by trivalent inactivated influenza vaccine boost with a 3.5 month interval, administered intradermally)
Number of subjects: 316
Study 31532789 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3-IIV3 (IIV3 prime followed by IIV3 boost with a 10 month interval, administered intramuscularly)
Number of subjects: 316
Study 31532789 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/IIV3-IIV3 (concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval)
Number of subjects: 316
Study 31532789 — intervention group
Group type: COMPARATOR
Intervention: IIV3 administered by ID route
Number of subjects: 316
Study 31532789 — intervention group
Group type: COMPARATOR
Intervention: IIV3 administered by IM route
Number of subjects: 316
Study 31532789 — intervention group
Group type: COMPARATOR
Intervention: DNA vaccine administered by Biojector
Number of subjects: 316
Study 27918240 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (AM; 9:00 h)
Number of subjects: 13
Study 27073876 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3 (per 10 nmol/L)
Number of subjects: 2877
Study 27073876 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3
Number of subjects: 2877
Study 24326593 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid-split approach
Number of subjects: 120
Study 24326593 — intervention group
Group type: COMPARATOR
Intervention: Deltopectoral approach
Number of subjects: 120